• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Should Investors Buy the Dip in Canopy Growth Stock?

Canopy's earnings losses could just be a stepping stone to becoming the industry leader.
By KEVIN CURRAN Jun 21, 2019 | 11:58 AM EDT
Stocks quotes in this article: CGC, CRON, MO, STZ, ACRGF

Despite a sharp decline in shares of Canopy Growth (CGC) after disappointing earnings results on Wednesday evening, many analysts following the stock believe the long-term outlook should provide confidence in a dip buying opportunity on CGC.

Shares of the Canadian cannabis leader are slated to close the week on a sour note, having fallen nearly 8% near midday as larger-than-expected losses, integration risks of major acquisitions, decelerating recreational use in Canada, and shrinking margins move the market to a cautious stance.

"There's just so many questions," Action Alerts PLUS portfolio manager Jim Cramer said. "That's why the stock is down."

However, as CEO Bruce Linton anticipates margins have reached their trough and the long-term outlook for cannabis remains in view, many on Wall Street consider this is just a growing pain of an emerging industry rather than a sign of a struggling company.

"We continue to estimate a $250-500 billion potential long-term global cannabis market, with a $15-50 billion near-term opportunity, and believe Canopy is well positioned in the sector," Piper Jaffray analyst Michael Lavery said. "We consider Canopy's topline revenue growth on track, and we expect growth to accelerate as industry-wide supply shortages subside and hemp-derived CBD products are commercialized in the US."

He noted that medical sales will likely carry growth in the future as supply lanes and distribution are ironed out as well, helping blunt the potential for recreational buyer fatigue. Further, he expects the large-scale investments and acquisitions the company is pursuing at present will provide significant growth in the long term.

"We recognize that there are some growing pains as Canada launches an entirely new industry segment, but we believe F4Q19 revenue growth was appropriate considering Canopy's F4Q19 capacity improvements are more likely to bear fruit in F1Q20," Lavery concluded.

Additionally, investors should not lose sight of the fact that Constellation Brands' (STZ) backing of the company for over $4 billion provides a significant lifeline amid near-term losses.

For example, it would likely be unthinkable for Canopy to acquire U.S. cannabis company Acreage Holdings (ACRGF) were it not for the major cash infusion it received in late 2018 from Constellation. While the $300 million buyout of the company will be a material impact in the coming quarter, Linton noted it expands the horizon for distribution and offers an important footprint in the U.S. market as bipartisan support for marijuana legalization builds.

Linton noted that the scale is important to both Canopy and Constellation, even if it tempers the results in the immediate term.

"If you look at Q3 fiscal 2018 Canopy had about 600,000 square feet of license facility and we understood this and delivered the margin, gross margin greater than 50% and we could have stayed there and we would have been a nice tidy little company probably quite profitable," Linton explained on Friday morning. "But what we thought was important is when you acquire a bigger supporting partner and they bring C$5 billion and there's a global opportunity, which we are in our opinion in the best position for, is use that capital to build scale and we did."

Linton acknowledged that this growth stage has hampered margins, but stated his belief that the reported 16% margin figure  represents the trough as higher-margin products such as candies, beverages, and vapes come into play more broadly and high charges on scale-building initiatives subside.

As such, the pain is sustainable and does not dampen much of the bullish sentiment emanating from major firms.

"As the company continues to ramp up its infrastructure, operating losses fell a bit shy of our expectations, further deepening from FQ3 levels," Canaccord Genuity analyst Matt Bottomley wrote to clients on Friday. "But given that the industry is still in a rather steep ramp-up phase and with C$4.5B of cash on its balance sheet, we are not overly concerned with profitability for the quarter."

Jim Cramer, who has touted the company as his top pick in the space, urged investors to eye the long term for such a nascent industry.

"They're spending like mad because they want to be the only guy," he explained. "They want to make a moat, they want to make it so no one else goes into the business because they are going to lose too much money."

Cramer noted that as of yet only Cronos Group  (CRON) , which has the backing of tobacco giant Altria  (MO) , can grit its teeth through losses to a similar extent. 

"I think it's an effective strategy, just not for shareholders right now," Cramer added. "I still like it because [CGC] ultimately will be the winner."

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Earnings | Investing | Stocks | Beverages | Marijuana | Pharmaceuticals | Canada | Analyst Actions | Cannabis | Stock of the Day

More from Stocks

Jim Cramer: Playing the Relative Investing Game

Jim Cramer
Mar 4, 2021 6:41 AM EST

Investing can be fun until it turns brutal for what seems to be no reason.

Corrective Action Continues as Support Levels Fall

James "Rev Shark" DePorre
Mar 4, 2021 6:24 AM EST

Dip buyers have lost confidence as selling momentum builds.

With This Market, It's One Way, or the Other

Helene Meisler
Mar 4, 2021 6:00 AM EST

Let's look at this either/or market and why investors are complacent and ... getting angry.

Don't Let the Rotation Deceive You: It Was Worse Than It Looked

James "Rev Shark" DePorre
Mar 3, 2021 4:48 PM EST

So-called reopening stocks hid some of the damage on the market, but here's what a deeper look tells me.

Compared to the Rest of the Market, International Game Tech Looks Pretty Good

Timothy Collins
Mar 3, 2021 3:12 PM EST

This isn't an aggressive trade in my view but I'm not sure I want to be aggressive here.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:50 AM EST PAUL PRICE

    Michaels: Close to a Deal?

    It appears that a deal could be announced soon. ...
  • 08:34 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 3/3/2021

    SPX (Long-Term View) The 20 DMA @ 3889 with the ...
  • 06:05 PM EST PAUL PRICE

    Michael's (MIK) Up on Takeover Rumors

    The NYT says talks are underway regarding a buyout...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login